Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 296 free, full-text research articles on human participants. First 3 results:

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
 

Author(s): Xianyin Lai, Mu Wang, Samantha Deitz McElyea, Stuart Sherman, Michael House, Murray Korc

Journal: Cancer Lett.. 2017 May;393():86-93.

 

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that often presents clinically at an advanced stage and that may be confused with chronic pancreatitis (CP). Conversely, CP may be misdiagnosed as PDAC leading to unwarranted pancreas resection. Therefore, early PDAC diagnosis ...

Last Updated: 24 Feb 2017

Go To URL
Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.
 

Author(s): Mu He, Zhixin Qiao, Yanbing Wang, Qiyuan Kuai, Changlan Li, Yu Wang, Xingwei Jiang, Xuanlin Wang, Weijing Li, Min He, Suping Ren, Qun Yu

Journal:

 

Pancreatic cancer is a fatal malignancy worldwide and urgently requires valid therapies. Previous research showed that the HDAC inhibitor chidamide is a promising anti-cancer agent in pancreatic cancer cell lines. In this study, we elucidate a probable underlying anti-cancer mechanism ...

Last Updated: 22 Nov 2016

Go To URL
Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells.
 

Author(s): Gui Yong-Xian, Li Xiao-Huan, Zhang Fan, Tian Guo-Fang

Journal: J Cancer Res Ther. 2016 Oct;12(Supplement):1-4.

 

The aim of the study is to investigate the underlying molecular mechanisms by which gemcitabine (gem) inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells in vitro.

Last Updated: 10 Oct 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 7 free, full-text review articles on human participants. First 3 results:

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
 

Author(s): Sheng Zhong, Shuai Qie, Liu Yang, Qi Yan, Linna Ge, Zhongfeng Wang

Journal: Medicine (Baltimore). 2017 Jul;96(30):e7611.

 

Pancreatic cancer (PC) is one of the most lethal digestive system tumors. Most new cases are diagnosed based on metastasis or local aggression and are known as "advanced PC." Recently, studies investigating S-1 have indicated that it has a better clinical curative effect on PC. We ...

Last Updated: 26 Jul 2017

Go To URL
Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
 

Author(s): Doudou Li, Changhao Chen, Yu Zhou, Rufu Chen, Xinxiang Fan, Zhuofei Bi, Zhihua Li, Yimin Liu

Journal: Medicine (Baltimore). 2015 Sep;94(35):e1345.

 

Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of GS versus GEM.Summary ...

Last Updated: 4 Sep 2015

Go To URL
S-1 in the treatment of pancreatic cancer.
 

Author(s): Kentaro Sudo, Kazuyoshi Nakamura, Taketo Yamaguchi

Journal: World J. Gastroenterol.. 2014 Nov;20(41):15110-8.

 

S-1 is an oral 5-fluorouracil (5-FU) prodrug, which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Recently, two important studies on the clinical use of S-1 for pancreatic cancer have been reported ...

Last Updated: 11 Nov 2014

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Screening for PDAC in BRCA1/2 Patients
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 8 Apr 2016

Go to URL
A Phase 1/2 Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
 

Status: Not yet recruiting

Condition Summary: Metastatic Pancreatic Cancer

 

Last Updated: 13 Jun 2017

Go to URL
Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 4 Sep 2016

Go to URL